everolimus + mycophenolic acid + tacrolimus

This is a combination immunosuppressive regimen consisting of three agents—everolimus, mycophenolic acid, and tacrolimus—commonly used in the prevention of organ transplant rejection, particularly in kidney transplantation. - **Everolimus** is a mammalian target of rapamycin (mTOR) kinase inhibitor that blocks cell cycle progression in activated T cells by inhibiting mTORC1, thereby suppressing immune responses[4][3]. - **Mycophenolic acid** inhibits inosine monophosphate dehydrogenase (IMPDH), leading to suppression of lymphocyte proliferation by blocking de novo guanosine nucleotide synthesis[6]. - **Tacrolimus** is a calcineurin inhibitor that prevents T-cell activation by inhibiting calcineurin phosphatase activity[2][5]. The combination leverages complementary mechanisms to provide potent immunosuppression and reduce the risk of acute rejection after transplantation. This regimen may be tailored for patients intolerant to one component or when minimization strategies are needed due to toxicity concerns. Clinical studies support its efficacy and safety as an alternative or adjunctive protocol for maintenance immunosuppression in renal transplant recipients[1][3].